Group 1 - Hong Kong Stock Exchange plans to launch the Hang Seng Biotechnology Index Futures on November 28, 2023, to enhance its derivatives product ecosystem [1] - The new futures contract will be based on the Hang Seng Biotechnology Index, which tracks the performance of the 30 largest biotechnology, pharmaceutical, and medical device companies listed in Hong Kong [1] - The biotechnology sector has become one of the hottest industries in the capital market, driven by technological innovation and global healthcare demand [1] Group 2 - Since the introduction of Chapter 18A in 2018, which allows unprofitable biotechnology companies to list in Hong Kong, 78 companies have successfully gone public, raising approximately 131.64 billion HKD [2] - The total market capitalization of these 18A companies has reached nearly 1.5 trillion HKD, covering key areas such as antibodies, small molecules, vaccines, and innovative medical devices [2] - Institutional investors' holdings in the top 30 Hong Kong-listed healthcare companies have increased from 13.3 billion USD in 2017 to 43 billion USD by June 30, 2025, with the biotechnology sector particularly favored [2] Group 3 - In the first half of 2025, the healthcare sector in Hong Kong completed 27 refinancing activities, raising a total of 3.9 billion USD, surpassing the total refinancing amounts for 2022, 2023, and 2024 [3] - The Hong Kong stock market has seen significant performance from healthcare stocks, especially 18A companies, with 27 out of 260 healthcare companies experiencing over 200% increase in stock prices this year [3] - Among the top 20 companies with the highest first-day stock price increases in the Hong Kong IPO market this year, 9 are healthcare companies, with 6 of them seeing increases over 100% [3]